Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — U.S. 2022

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Anderson, Tara C. ; Masters, Nina B. ; Guo, Angela ; Shepersky, Leah ; Leidner, Andrew J. ; Lee, Grace M. ; Kotton, Camille N. ; Dooling, Kathleen L.
• Description:
  Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit vaccine containing recombinant glycoprotein E in combination with adjuvant (AS01|) that was licensed in the U.S. for Prevention of herpes zoster for adults aged ≥50 years by the Food and Drug Administration (FDA) and recommended for immunocompetent adults aged ≥50 years by the Advisory Committee on Immunization Practices (ACIP) in 2017* (1). On July 23, 2021, the FDA expanded the indication for recombinant zoster vaccine (RZV) to include adults aged ≥18 years who are or will be at increased risk for herpes zoster because of immunodeficiency or immunosuppression caused by known disease or therapy (2). On October 20, 2021, ACIP recommended 2 doses of RZV for the Prevention of herpes zoster and related Complications in adults aged ≥19 years| who are or will be immunodeficient or immunosuppressed because of disease or therapy. RZV is the first herpes zoster vaccine approved for use in immunocompromised persons. With moderate to high vaccine efficacy and an acceptable safety profile, RZV has the potential to prevent considerable herpes zoster incidence and related Complications. This report updates previous ACIP Rec.for the Prevention of herpes zoster (1,3).
• Subjects:
  Adult Advisory Committees Drug Approval Herpes Zoster Herpes Zoster Vaccine Humans Immunocompromised Host Middle Aged Vaccines, Synthetic
• Source:
  MMWR Morbidity Mortal Weekly Rep. 71(3):80-84
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/MMWRmm7103a2
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  35051134
• Pubmed Central ID:
  PMC8774159
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  5 pdf pages
• Volume:
  71
• Issue:
  3
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:1ad647f2e4a9d93746959df3765cda8b05524b2f2b0b2e487a0fa77f3be1714694f5c74dd516df14285b84678729b1faacfd3c87e373984ba5ec1f5e94e5e32d
• Download URL:
  https://stacks.cdc.gov/view/cdc/114308/cdc_114308_DS1.pdf
• File Type:
  [PDF - 111.71 KB ]